Updated tumor agnostic efficacy of selpercatinib in patients with RET fusion-positive solid tumors: LIBRETTO-001

被引:0
作者
Ohe, Y. [1 ]
Subbiah, V. [2 ]
Sukrithan, V. [3 ,4 ]
Robinson, B. [5 ]
Deschler-Baier, B. [6 ]
Iwasa, T. [7 ]
Ohashi, K. [8 ]
Goto, K. [9 ]
Nishio, M. [10 ]
Satouchi, M. [11 ]
Nakamura, K. [12 ]
Ashiguchi, S. [12 ]
Lin, Y. [13 ]
Szymczak, S. [13 ]
Drilon, A. [14 ]
机构
[1] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[3] Ohio State Univ, Div Med Oncol, Columbus, OH USA
[4] Arthur G James Canc Ctr, Columbus, OH USA
[5] Royal North Shore Hosp, Dept Endocrinol, St Leonards, NSW, Australia
[6] Univ Hosp Wurzburg, Comprehens Canc Ctr, Wurzburg, Germany
[7] Kindai Univ, Dept Med Oncol, Fac Med Dept, Osaka, Japan
[8] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[9] Natl Canc Ctr East, Dept Thorac Oncol, Chiba, Japan
[10] Canc Inst Hosp JFCR, Dept Thorac Med Oncol, Tokyo, Japan
[11] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Japan
[12] Eli Lilly Japan KK, Japan Drug Dev & Med Affairs, Kobe, Japan
[13] Eli Lilly & Co, Indianapolis, IN USA
[14] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
关键词
D O I
10.1016/j.annonc.2024.07.652
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
O14-2
引用
收藏
页码:S1322 / S1322
页数:1
相关论文
empty
未找到相关数据